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ABSTRACT
Cdx2, a gene of the paraHox cluster, encodes a
homeodomain transcription factor that plays
numerous roles in embryonic development and in
homeostasis of the adult intestine. Whereas Cdx2
exerts a tumor suppressor function in the gut, its
abnormal ectopic expression in acute leukemia is
associated to a pro-oncogenic function. To try to
understand this duality, we have hypothesized that
Cdx2 may interact with different protein partners in
the two tissues and set up experiments to identify
them by tandem affinity purification. We show
here that Cdx2 interacts with the Ku heterodimer
specifically in intestinal cells, but not in leukemia
cells, via its homeodomain. Ku proteins do not
affect Cdx2 transcriptional activity. However, Cdx2
inhibits in vivo and in vitro the DNA repair activity
mediated by Ku proteins in intestinal cells. Whereas
Cdx2 does not affect the recruitment of Ku proteins
and DNA-PKcs into the DNA repair complex, it
inhibits DNA-PKcs activity. Thus, we report here a
new function of Cdx2, acting as an inhibitor of the
DNA repair machinery, that may contribute to its
tumor suppressor function specifically in the gut.
INTRODUCTION
The Cdx2 gene, a member of the paraHox cluster, plays
numerous roles in embryos including trophectoderm
differentiation, posterior elongation and patterning, and
intestinal determination (1–3) By midgestation onwards,
it becomes restricted to the intestinal epithelium and is
later involved in the homeostasis of the adult gut (4–6).
The primary function of Cdx2 depends on its activity of
DNA-binding transcription factor (7), but recent data
suggest that it can also act via non-conventional
mechanisms. For instance, it interacts with Smad3 to
activate TGFb reporter systems in the absence of TGFb
(8). Cdx2 is also able to interact with the p65 subunit of
NFkB and therefore prevent the NFkB binding and
activation of the Cox-2 promoter (9,10). Similarly, by
interacting with b-catenin, and consequently preventing
the recruitment of b-catenin on Tcf4, Cdx2 interferes
with Wnt signalling (11). Recently, Cdx2 has also been
reported to inhibit cell proliferation by stabilizing the
cell cycle regulator p27Kip1 independently of its
DNA-binding activity (12).
Cdx2 deregulation has several outcomes in pathological
situations. In the normal site of expression, the gut, it
becomes reduced and heterogeneous in human colorectal
cancers. Experimentally, the reduced expression of Cdx2
in Cdx2
+/  mice facilitates tumor progression in models
of genetically and chemically induced intestinal cancers
(13–14), and it also increases the migration and dissemin-
ation of colon cancer cells (15). Together, these data led to
attribute a tumor suppressor role to Cdx2 in the gut.
However, beside the gut, Cdx2 is ectopically expressed in
a number of pathologies including acute leukemia, where
it has been described as an oncogene since forced expres-
sion in haematopoietic progenitors induces leukemia
(16,17). Thus, Cdx2 has opposite effects depending on
the tissue context in sites of normal or ectopic expression.
Interestingly, the susceptibility of Cdx2
+/  mice to in-
testinal cancer has been correlated to a higher resistance of
the colon epithelium to g-irradiation-induced apoptosis
and to an increased chromosomal instability (13,14).
In line with this, Cdx2 suppresses cell proliferation by
blocking G0/G1-S progression at the ﬁrst DNA check-
point (12). These observations open the possibility that
Cdx2 may have a role in genome maintenance and DNA
repair. Double-strand DNA breaks (DSBs) induced
by many pro-oncogenic stresses, like oxidative stress or
radiations, play a major role in cancer. Indeed, massive
unrepaired DSBs lead to cell cycle arrest or apoptosis
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ations due to chromosomal translocation or mutations
(18). In higher eukaryotes, the non-homologous DNA
end-joining (NHEJ) repair mechanism prevails when
DSBs occur, notably during G1 phase of the cell cycle
(19). During this process, the Ku antigen heterodimer
(Ku70/Ku80) recognizes broken DNA ends and allows
the recruitment of the repair machinery, including
DNA-PK and ligase IV. The lack of either Ku antigen
or DNA-PK large catalytic subunit (DNA-PKcs) contrib-
utes to high radiosensitivity, immunodeﬁciency and
premature aging (20–22).
The reason why Cdx2 has opposite effects in various
pathological settings, especially in colon cancers and
leukemia, remains elusive. One possibility is that the
function of this homeoprotein depends on the cellular
context, or in other words that Cdx2 interacts with differ-
ent partners in different tissues, leading to different effects.
In the present work, we challenged this hypothesis, which
allowed us to identify the Ku heterodimer as a partner of
Cdx2 speciﬁcally in intestinal cells but not in leukemia
cells. Functional studies provided evidence for a new
and unexpected role of the Cdx2 protein, as a regulator
of the DNA repair machinery.
MATERIELS AND METHODS
Cell lines, plasmids and cell transfections
HCT116, SW480, K562 and Nalm6 were grown as recom-
mended (40–43). HT29-TW6, -TW10 or -TG8 cells have
been described previously (15). pFlag-Cdx2 and pFlag-
miniCdx2 have been described (26) pFOXO4 and 6DBE-
luc plasmids have been described (27). Mutant plasmids
were prepared in pFlag2 vector (Sigma Aldrich, St. Louis,
MO, USA). DNA fragments were ampliﬁed from
pFlag-Cdx2 using the 50 primer AAAAAGCTTTCCCT
CGGCAGCCAAGTGAAA and the 30 primers AAAAG
ATCTAGTTCCCGAGACCCTGTGAAG and AAAAG
ATCTACGGCGACGTCTTGGGCCA for
Cdx2[175-250] and Cdx2[175-313], respectively, and the
50 primer AAAAAAGCTTTACGTGAGCTACCTCCT
GGACAAGG and 30 primer AAAAGATCTCGTTGA
AGAAGAACAACTAAAAGG for Cdx2[1-220].
pCTAP-Cdx2 was prepared by cloning the human Cdx2
cDNA ampliﬁed with the primers 50AAAAAGCTTGCC
ACCATGTACGTGAGCTACTCCTGGACAAGGAC
G3 0,5 0AAAGTCGACCTGGGTGACGGTGGGGTTT
AGCA 30 into HindIII/SalI digested pCTAP-A vector
(Agilent Technologies, Santa Clara, CA). For SI-luc and
CDH17-luc plasmids construction, the two promoter
regions were ampliﬁed from human DNA using primers
AAAGAGCTCCACAGCTTTGAGAAATCAAAGA
and AAAAAGCTTGCCTGTTCTCTTTGCTATGTTG
T for SI promoter and AAAGAGCTCTTTCACTTGC
AGGGTCCTCAGG and AAAAAGCTTCGAGACTC
TTGCTACGACTGGA for CDH17 promoter. DNA
were then cloned into SacI and HindIII sites of pGl3-
basic vector (Promega, Madison, WI) Underlined
sequences indicate restriction sites inserted and used for
cloning. Colon cancer cells transfections were performed
using JetPEI (Polyplus Transfection, Illkirch, France) or
Lipofectamin2000 (Invitrogen, Carlsbad, CA, USA) and
leukemia cells were nucleofected using the Amaxa system
(program X1; Lonza, Basel, Switzerland), as recom-
mended by the suppliers in Viaspan buffer (Bristol-
Myers Squibb Pharmaceuticals, Dublin, Ireland).
Luciferase activity measurement
For luciferase activity measurement, 1.5 10
5 cells were
co-transfected with 100ng of reporter plasmid (SI-luc and
CDH17-luc) together with 10ng of Cdx2 and Ku70, Ku80
encoding plasmids when indicated 200ng of reporter
6DBE-luc together with 200ng of FOXO4 and Ku70
encoding plasmids when indicated. pRL-null was used as
internal control (Promega, Madison, WI, USA). Fireﬂy
and Renilla luciferase activities were measured using a
dual reporter luciferase assay (Promega, Madison, WI)
with a Lumistar luminometer (BMG, Offenburg,
Germany) 48h after DNA transfection. Each transfection
experiment was repeated at least three times in triplicate.
Fireﬂy luciferase activity was normalized with Renilla
luciferase activity.
Antibodies and western blot
Proteins separated on SDS–PAGE were analyzed by
western blot using different primary antibodies: mouse
monoclonal anti-Cdx2 (CDX2-88, BioGenex, San
Ramon, CA, USA; 1/2000), goat polyclonal anti-Ku70
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1/
2000), rabbit polyclonal anti-Ku70 (Millipore, Billerica,
MA, USA; 1/5000), mouse monoclonal anti-Ku70
(S5C11, Abcam, Cambridge, MA, USA; 1/10000),
rabbit monoclonal anti-Ku80 (EPR3468, Abcam,
Cambridge, MA, USA; 1/10000), mouse monoclonal
anti-Flag (M2 afﬁnity puriﬁed, Sigma Aldrich, St Louis,
MO, USA; 1/4000), rabbit polyclonal anti-DNA-PKcs
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1/
200), rabbit polyclonal anti S2056-phosphorylated DNA-
PKcs (Abcam, Cambridge, MA, USA; 1/200), mouse
monoclonal anti-b-actin (C4, Millipore, Billerica, MA,
USA; 1/25000). HRP-conjugated anti-mouse or anti-
rabbit secondary antibodies (GE company, Fairﬁeld,
CT, USA) were used before ECL detection (GE
company, Fairﬁeld, CT, USA).
Cell survival assay of colon cancer cells
HCT116 cells (3 10
6) were transfected for 24h or
HT29-TW6, -TW10 or –TG8 cells were treated with
vehicle or doxycyclin (1mgml
 1; Sigma Aldrich, St Louis,
MO, USA) for 24h. Cells were washed in PBS and treated
by 20mM etoposide (Sigma Aldrich, St Louis, MO, USA)
containing medium for 24h (with 1mgml
 1 of doxycyclin
for HT29 cells). Cells were trypsinized and 1 10
6 cells
were seeded in culture medium (with 1mgml
 1 doxycyclin
for HT29), grown in 25 cm
2 for 2 weeks. Adherent cells
were ﬁxed with 70% ethanol, stained with 0.1% crystal
violet and colonies were estimated by ImageJ software (W
Rasband, Bethesda, MA, USA).
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Nalm6 or K562 cancer cells (5 10
6 cells) were
nucleofected with 5mg plasmid and cultured for 24h for
recovering. Nucleofected cells were treated with 60mMo f
etoposide for 24h. Apoptotic cell number was estimated at
indicated time point on the FACScalibur machine (BD
Biosciences, Franklin Lakes, NJ, USA) using a
green-versus-red ﬂuorescent plot after staining cells
10min with 2.5mgml
 1 FITC-labeled annexin V (Roche
Diagnostics, Mannheim, Germany) in buffer AP (10mM
HEPES/NaOH, pH 7,4, 150mM NaCl, 5mM Kcl, 1mM
MgCl2, 1,8mM CaCl2) supplemented with 10mgml
 1
propidium iodide (Sigma Aldrich, St Louis, MO, USA).
Annexin V positive cells (PI negative and positive) were
considered as dead cells.
In situ protein–protein interaction assay (DuoLink)
SW480 cells seeded in eight-well CultureSlides (BD
Biosciences, Mountain View, CA, USA) were ﬁxed (PFA
4%, 15min) and permeabilized (Triton X-100 0.5% in
PBS, 30min). Slides were processed for in situ Proximity
Ligation Assay following manufacturer’s instructions
using the Duolink II Detection Reagents Green,
Duolink II PLA probe anti-Mouse Plus, Duolink
II PLA probe anti-Rabbit Minus (Olink Bioscience,
Uppsala, Sweden), and mouse anti-Cdx2, and rabbit
anti-Ku70 or rabbit anti-Ku80 as primary antibodies. To
check the speciﬁcity of the PLA signal, control experi-
ments omitting one of the primary antibodies were
performed. Imaging was performed using an Imager.Z2
microscope and Axiovision software (Zeiss, Jena,
Germany). Nuclei were labeled with DAPI 1mgml
 1.
Tandem afﬁnity puriﬁcation (TAP-Tag)
For tandem afﬁnity puriﬁcation of Cdx2 containing
complex, we used the InterPlay mammalian TAP
system (Agilent Technologies, Santa Clara, CA, USA).
For puriﬁcation, 12 10
6 HCT116 were transfected with
72mg of pCTAP or pCTAP-Cdx2, 24 10
6 SW480 with
96mg of pCTAP or pCTAP-Cdx2 and 100 10
6 NALM6
or K562 cells were nucleofected with 5mg of pCTAP or
pCTAP-Cdx2 for 5 10
6 cells. Double-tagged protein was
recovered according to manufacturer’s protocol. Proteins
were eluted in 125mlo f2   laemmli buffer and boiled. The
recovered proteins were separated on a 14-cm long
7.5–15% gradient gel together with a prestained protein
ladder (Euromedex, Strasbourg, France), silver stained
(PlusOne
TM Silver Staining Kit, GE company, Fairﬁeld,
CT, USA) and analyzed by mass spectrometry. Gel slices
containing protein bands of interest were excised and pro-
cessed as described previously (44). After digestion, the
resulting peptide extracts were directly analyzed by
nanoLC-MS/MS using an Agilent 1100 series
nanoHPLC-Chip/MS system (Agilent Technologies, Palo
Alto, USA) coupled to a HCT Plus ion trap (Bruker
Daltonics, Bremen, Germany). Mass data collected
during the nanoLC-MS/MS analysis were processed and
converted into *.mgf ﬁles using the DataAnalysis 3.3 Build
146 software (Bruker Daltonics, Bremen, Germany). The
MS and the MS/MS data were searched using a local
Mascot server (MASCOT 2. 2.0, MatrixScience, UK)
against a composite target-decoy database including the
SwissProt 55.5 protein sequences. Mascot results were
loaded in MuDPIT mode into the Scaffold 2.00.03
software (Proteome Software, Portland, USA).
Immunoprecipitation
Cells were rinsed with PBS and lysed for 30min in lysis
buffer [10 mM Tris–HCl pH 7.4, 150mM NaCl, 1mM
EDTA, 1% Triton X-100, 1% NP-40, 1mM EGTA and
protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany)]. The lysate was centrifuged at
20000g for 20min at 4 C. One mg of protein was
incubated with 2mg of primary antibodies in 1ml of lysis
buffer overnight at 4 C with gentle rocking.
Immunoprecipations were performed with 30ml of 50%
G- or A-agarose beads (Roche Applied Science) for 2h
at 4 C. Immunoprecipitates were washed twice with lysis
buffer, twice with lysis buffer containing 500mM NaCl
and eluted using SDS–PAGE sample loading buffer
(Biorad, Hercules, CA, USA). When precised, HCT116
cell extracts (1mgml
 1) were treated for 30min with
400mgml
 1 Ethidium Bromide (EtBr) prior to addition
of antibodies.
In vivo reparation assay
pEGFP-Pem1-Ad2 plasmid was kindly provided by G.
Iliakis (Essen, germany). HindIII restricted pEGFP-
Pem1-Ad2 was puriﬁed using Qiagen PCR puriﬁcation
kit (Qiagen, Hilden, Germany), ethanol precipitated and
resuspended in water. One day after splitting, exponential-
ly growing cells were transfected with 10ng of digested
plasmid pEGFP-Pem1-Ad2, 10ng of pCherry (Clontech,
Mountain View, CA, USA) as an internal control and
0.8mg of pFlag or wt/mutant Cdx2 encoding plasmid.
Cells were analyzed on the FACScalibur machine
(BD Biosciences, Mountain View, CA) using a green-
versus-red ﬂuorescent plot. Cells with repaired
pEGFP-Pem1-Ad2 DNA are identiﬁed in the up-right
panel. Results are represented as the percentage of green
and red cells in the red cells population.
In vitro DNA repair assay
Cell free extract was prepared as described (45). Brieﬂy,
48h after transfection, 3 10
7 cells were washed in cold
PBS, resuspended in four packed cell volumes of cold
hypotonic lysis buffer A (10mM Tris–HCl pH 7.6,
1mM DTT, 5mM MgCl2, 1mM EDTA and protease
inhibitors), incubated for 40min on ice and then disrupted
using a Dounce homogenizer (40 strokes). Subsequently,
sucrose was added to reach a ﬁnal concentration of
250mM. The extract was homogenized and centrifuged
10min at 1000g to discard cell debris, and then washed
again in the hypotonic lysis buffer containing 250mM
sucrose. Nuclear pellet was then resuspended in two
volumes of nuclear extraction buffer B (20mM Tris–Hcl
pH 7.6, 1mM DTT, 2mM EDTA, 20% glycerol, 500mM
NaCl and protease inhibitors) and incubated for 30min
on ice. Nuclear extracts were then clariﬁed 30min at
3458 Nucleic Acids Research, 2012,Vol.40, No. 821000g and dialysed overnight against dialysis buffer
D (20mM Tris–HCl pH 7.6, 1mM EDTA, 1mM DTT,
20% glycerol, 25mM NaCl and 0.2mM PMSF).
End-joining reaction was performed in a ﬁnal volume of
30ml by incubating 50ng of BamHI digested pcDNA3
plasmid with 5mg of nuclear extract for 1h at 37 Ci n
buffer E (50mM Tris–HCl pH 7.6, 5mM MgCl2,1 m M
ATP, 1mM DTT, 50mM dNTP, 80mM NaCl and
protease inhibitors). Reaction was stopped by RNAse
treatment (0.25mgml
 1 of RNAse for 10min at 37 C)
followed by a proteinase K treatment (0.5% SDS, 50mM
EDTA and 1mgml
 1 of proteinase K at 37 C for 1h). DNA
was puriﬁed by phenol and chloroform extraction and
recovered by ethanol precipitation, separated on a 0.85%
agarose gel at 2Vcm
 1 and visualized by UV light.
Wortmanin (Sigma Aldrich, St Louis, MO, USA) was
prepared in DMSO at 10mM and diluted in 10% DMSO
to 20mM immediately before use. Diluted wortmanin
(1ml) was added to the reaction and incubated for
10min at 4 C prior the addition of ATP and DNA.
DNA ends-binding activity of Ku70
Preparation of nuclear extracts and assessment of DNA
ends-binding activity of Ku70 were carried out using a
Nuclear Extract kit and a Ku70/Ku80 DNA Repair
Protein ELISA kit (Active Motif, Carlsbad, CA, USA).
In brief, 3 10
6 HCT116 cells were transfected with 8mg
of pFlag or pFlag-Cdx2 plasmid and nuclear proteins
were extracted following the kit instructions. Equivalent
amounts of proteins (5mg) from each lysate were loaded
into wells coated with blunt ends linear oligonucleotides
that can be speciﬁcally bound by Ku70 protein. Amount
of bound Ku70 was quantiﬁed by using the provided
anti-Ku70 primary antibody and the secondary
HRP-conjugated antibody in a sensitive colorimetric
assay using the Universal Microplate Reader EL800UV
(Biotek Instruments, Winooski, VT, USA).
DNA-PKcs activity assay
At 48h after Cdx2 induction by Doxycyclin, cells were
treated with etoposide (50mM), neocarzinostatin
(200ngml
 1; Sigma Aldrich, St Louis, MO, USA) or
DMSO for 1h. The amount of p53 phosphorylated on
serine 15 is measured following the PathScan Sandwich
ELISA Kit instructions (Cell Signaling Technology,
Danvers, MA, USA). Brieﬂy, an aliquot of 10ngml
 1 of
cell extract is added to a microwell coated with p53
antibodies and incubated overnight at 4 C. The amount
of phospho-p53 is quantiﬁed by spectrophotometry by
using a phosphoSer15-p53 speciﬁc antibody revealed by
the provided HRP-conjugated secondary antibody. The
absorbance is read at 450nm with the Universal
Microplate Reader EL800UV (Biotek Instruments,
Winooski, VT, USA).
RT-qPCR
Total RNA was isolated using TRI-Reagent (Ambion
Applied Biosystem, Houston, TX, USA). For reverse
transcription, we used the high capacity reverse transcrip-
tion kit (Applied Biosystems, Carlsbad, CA, USA) and
2mg of RNA. For qPCR, we used TaqMan Universal
PCR Master Mix (Applied Biosystems, Carlsbad, CA,
USA), TaqMan human TBP, CDH17 and SI probes
(TBP, Hs99999910_m1; CDH17, Hs00184865_m1; SI,
Hs00356112_m1; Applied Biosystems, Carlsbad, CA),
and 7500 Real-Time PCR system (Applied Biosystems,
Carlsbad, CA, USA). Results analysis was performed
using the Applied 7500 Software v2.0.1.
Statistics
The results were analyzed using GraphPad Prism version
5.0. Mean of results of at least three independent experi-
ments with SEM is generally represented. The statistical
difference of the mean was analyzed using Student’s
paired two-tailed t-test.
RESULTS
Identiﬁcation of Ku70/Ku80 proteins as speciﬁc partners
of Cdx2 in intestinal cells
In an attempt to identify Cdx2 interacting proteins, we
used the TAP-Tag technology (Tandem Afﬁnity
Puriﬁcation). For this purpose, we expressed a double
tagged Cdx2 protein, containing at its C-terminus end
CBP (Calmodulin Binding Protein) and SBP (Streptavidin
Binding Protein) motives, in two human colon cancer cell
lines that express endogenous Cdx2 either at high (SW480)
or low levels (HCT116), and in two leukemia cell lines that
also express Cdx2 at intermediate (Nalm6) or very low
levels (K562). The puriﬁed proteins were separated on
SDS–polyacrylamide gels and silver stained. This
revealed distinct patterns in intestinal and leukemia cells,
mainly in the region corresponding to proteins of
70–90kDa. Indeed, two bands appeared in this region in
both intestinal cell lines but were virtually absent in the
two leukemia cell lines (Figure 1A). Mass spectrometry
analysis of the proteins present in this region identiﬁed
the Ku70 and Ku80 proteins, speciﬁcally in the intestinal
cells as opposed to leukemia cells. This result combining
TAP-Tag puriﬁcation and mass spectrometry analysis was
repeated in three separate experiments.
We wondered whether the different Cdx2 interaction
patterns observed in intestinal and leukemia cells
resulted from a different level of expression of Ku70 and
Ku80 in these cells. Western blot analysis revealed that
both proteins were expressed at nearly similar levels in
intestinal and leukemia cells (Figure 1B), indicating that
the absence of interaction with Cdx2-CBP-SBP in
leukemia cells did not reﬂect a loss of Ku70 or Ku80 ex-
pression, but instead a differential interaction capacity.
The interaction of Cdx2 with Ku70/80 uncovered by
TAP-Tag puriﬁcation in intestinal cells used transfected
cells to produce high levels of Cdx2-CBP-SBP. Two
series of experiments were performed to rule out any tech-
nical artifact and to actually demonstrate the interaction
at the level of the endogenous proteins. For this purpose,
we used the intestinal SW480 cells that express both Ku70/
80 and Cdx2 proteins. First, coimmunoprecipitations of
endogenous proteins were performed. As illustrated in
Figure 1C, antibodies raised against Ku70 or Ku80
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anti-Cdx2 antibody coimmunoprecipitated the Ku70 and
Ku80 proteins. These results were conﬁrmed in DLD1, an
intestinal cell line that also expresses endogenous Cdx2 at
a relatively high level, and in HT29 and HCT116 cells
after overexpression of Cdx2 since these two intestinal
cell lines express only barely detectable levels of endogen-
ous Cdx2 (Supplementary Figure S1 and Figure 2).
Second, we used the Proximity Ligation Assay (PLA)
technology that is appropriate to reveal the proximity of
two proteins in situ in the cells (23). The Figure 1D shows
that both anti-Ku70 and anti-Ku80 antibodies produced a
positive ﬂuorescent signal in the nuclei of SW480
cells when combined with anti-Cdx2 antibody, indicating
the interaction of the two proteins in this cell
compartment. Altogether, these results demonstrate
that the Ku70, Ku80 and Cdx2 proteins can associate
within a same nuclear multiprotein complex in intestinal
cells.
Coimmunoprecipitations performed in Nalm6 and
K562 leukemia cells failed to reveal any interaction
between Cdx2 and Ku proteins, consistent with the
absence of the Ku protein in the TAP-Tag experiments
(Supplementary Figure S1).
Cdx2 interacts with Ku70/Ku80 via the third a-helix of
the homeodomain
Two homeoproteins of the Hox clusters, HoxB7 and
HoxC4, have been shown to interact with Ku70, and the
homeodomain was demonstrated to be essential for this
interaction (24,25). To delineate the domain of interaction
with Ku proteins within the Cdx2 homeoprotein, we con-
structed plasmids encoding truncated forms of Cdx2,
which were all Flag-tagged at their N-terminus: the
miniCdx2 form corresponds to a splicing variant of
Cdx2 in which the transactivation domain is replaced by
a 13 amino acids extension at its N-part (26); the mutant
Figure 1. Cdx2 interacts with Ku70/Ku80 proteins. (A) Silver-stained protein gel obtained after tandem afﬁnity puriﬁcation from K562, Nalm6,
HCT116 and SW480 cells transfected with pCTAP-Cdx2. M: molecular weight protein ladder. Cdx2-CBP-SBP (Cdx2-cs) and Ku70/Ku80 proteins
are indicated with gray or black arrowheads, respectively. (B) Western blot revealing the presence of Ku70 and Ku80 proteins in all studied cell lines.
Nearly 20mg of total proteins were separated on a gradient SDS–PAGE. Actin was used as loading control. (C) Coimmunoprecipitation of
endogenous Cdx2 and Ku proteins. SW480 extracts were prepared and Cdx2, Ku70 or Ku80 were immunoprecipitated using corresponding
antibodies. Mouse IGg (M-IGg) or rabbit IGg (R-IGg) were used as negative control. Western blot was revealed using rabbit anti-Ku70 and
rabbit anti-Ku80 in the upper panel and using mouse anti-Cdx2 in the lower panel. About 20mg of protein extracts were loaded in the input line.
(D) In situ proximity ligation assay. Mouse anti-Cdx2 and rabbit anti-Ku70 (left panel) or mouse anti-Cdx2 and rabbit anti-Ku80 antibodies (right
panel) were used to reveal endogenous proteins in SW480 cells. Green ﬂuorescence corresponds to the PLA positive signal and indicates that the two
molecules belong to the same protein complex; blue ﬂuorescence corresponds to nuclei (DAPI staining). Red bar is 10mm.
3460 Nucleic Acids Research, 2012,Vol.40, No. 8Cdx2[175–313] overlaps the homeodomain and the
C-terminal regulatory region but lacks the transactivation
domain; the mutant Cdx2[1–220] contains the transactiva-
tion domain and the ﬁrst two a-helixes of the
homeodomain but has lost the third a-helix and the down-
stream regulatory region; the mutant Cdx2[175–250]
contains the full-length homeodomain without the N-ter
transactivation domain and the C-ter regulatory domain
(Figure 2A). After transfection of these plasmids into
HCT116 colon cancer cells, coimmunoprecipitation ex-
periments were performed using anti-Flag antibody. The
full-length Cdx2 protein, the miniCdx2 variant, and the
mutants containing an intact homeodomain, Cdx2[175–
250] and Cdx2[175–313], co-immunoprecipitated Ku70
and Ku80; however, the mutant lacking the third a-helix
of the homeodomain, Cdx2[1–220], did not interact with
Ku proteins (Figure 2B). These data indicate that the
homeodomain is involved in the interaction of Cdx2
with the Ku70/80 complex and that the third a-helix is
required for this interaction.
The Ku70/Ku80 complex does not alter Cdx2
transcription activity
To take up the biological relevance of the interaction
between Cdx2 and Ku70/80, we ﬁrst addressed the issue
of the impact of Ku proteins on the transcriptional
activity of Cdx2. For this goal, HCT116 cells were trans-
fected with the plasmid encoding Cdx2 together with com-
binations of plasmids encoding Ku70 and Ku80.
Then, the expression of two well-established targets
of Cdx2, the liver–intestine cadherin (CDH17) and
the sucrase-isomaltase (SI) genes was analyzed by RT-
qPCR. Cdx2 alone strongly stimulated the expression of
both genes, and the level of stimulation was not signiﬁ-
cantly modiﬁed in the presence of Ku70 and/or Ku80
(Figure 3A). To corroborate these results, HCT116 cells
were cotransfected with reporter luciferase plasmids con-
taining the promoter of the CDH17 or SI genes with their
Cdx2-responding elements. Again, Cdx2 stimulated the
basal activity of these promoters, but Ku70 and/or Ku80
did not signiﬁcantly change the stimulatory effect exerted
by Cdx2 (Figure 3B, left and middle panels). In the same
conditions, Ku70 inhibited the transcriptional activity of
the FOXO4 transcription factor (Figure 3B, right panel),
as previously described (27). We conclude from these data,
that, albeit Ku70/80 interacts with Cdx2, it does neither
stimulate nor inhibit its transcriptional activity.
Cdx2 inhibits in vitro DNA repair speciﬁcally in intestinal
cell lines
We then asked whether Cdx2 may affect the function of
Ku70/80 proteins. The Ku70/80 heterodimer is largely
involved in DNA repair. Indeed, the mechanism of
DNA repair primarily activated by DSBs, namely
C-NHEJ, is dependent on Ku70/80, on the wortmanin-
sensitive DNA-PK and on ATP. Ku protein heterodimers
bind and encircle broken DNA, allowing the recruitment
of DNA-PKcs and DNA-ligase IV. Under conditions pre-
venting the activation of C-NHEJ, for example when
Ku70/80 heterodimers fail, an alternative pathway,
named A-NHEJ, can be turned on to compensate the
missing activity of C-NHEJ. Whereas C-NHEJ is primed
by the binding of Ku70/80 on the broken DNA ends,
A-NHEJ is activated in the absence of Ku70/80 by the
recognition of the DNA ends by PARP-1 (28,29).
DNA repair can be assayed in vitro by incubating linear
DNA with nuclear extracts and measuring the appearance
of slow-migrating electrophoretic DNA fragments corres-
ponding to circularized and multimeric forms (30). We set
up this assay and conﬁrmed previous data by Fattah et al.
(28) showing that the C-NHEJ pathway is predominant in
intestinal HCT116 cells since DNA repair is wortmanin-
sensitive and insensitive to PARP1 antibody (Figure 4A,
left). In addition, when cells were transfected with
siRNA@Ku70 to deplete the nuclear extracts in Ku70,
the DNA repair activity became wortmanin-insensitive,
but signiﬁcantly decreased in the presence of anti-PARP-
1 antibody (Figure 4A, right), indicating that, in these
conditions, DNA repair involves the A-NHEJ instead of
the C-NHEJ pathway.
Figure 2. The homeodomain of Cdx2 is necessary for its interaction
with Ku70/Ku80. (A) Schematic representation of the different Cdx2
deletion mutants tested. TAD: transactivator domain; NLS: nuclear
localization signal; HD: homeodomain; SD: stabilization domain. The
upper numbers represents the position of the different domains in the
313aa long Cdx2 protein. (B) Coimmunoprecipitations of the different
mutant proteins with Ku proteins. Co-IP was performed in HCT116
transfected with the indicated mutant plasmids using anti-Flag
antibodies. Immunoprecipitates were separated on a SDS–PAGE and
analyzed by western blot using anti-Ku70 and anti-Ku80 antibodies
(upper panel), anti-Flag antibodies (middle panel). Ku70 and Ku80
proteins present in the protein extracts before immunoprecipitation
were revealed by western blot (input, lower panel).
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Cdx2 has any effect on the NHEJ activity in intestinal
cells. For this purpose, nuclear extracts were prepared
from HCT116 cells transfected either with the pFlag2
vector as control or with expression plasmids encoding
Cdx2 or truncated forms of the protein. As shown in
Figure 4B, the DNA repair activity observed by
incubating linear DNA with control nuclear extracts was
inhibited when Cdx2 was present in the extracts. Omitting
ATP in the reaction mix also strongly compromised DNA
repair activity. Consequently, since Cdx2 inhibits the
overall DNA repair activity while Ku70/80 is present in
the nuclear extracts, we concluded that Cdx2 compromises
C-NHEJ activity without turning on the A-NHEJ
pathway.
To strengthen this conclusion, we analyzed the depend-
ency of the inhibitory effect exerted by Cdx2 on the
interaction between Cdx2 and Ku70/80. DNA repair
activity determined using the in vitro assay was inhibited
by Cdx2 as well as miniCdx2 (Figure 4C) which both
interacted with Ku70/80 (Figure 2B). Inversely, the
truncated Cdx2[1–220] mutant, that failed to interact
with Ku70/80, did not inhibit DNA repair, demonstrating
that the physical interaction between Cdx2 and the Ku70/
80 complex is required for Cdx2 to exert its inhibitory
effect of C-NHEJ activity.
Having demonstrated on the one hand that Cdx2 inter-
acts with Ku70/80 in intestinal cells to inhibit the
Ku70/80-dependent DNA repair activity via the
C-NHEJ pathway, and on the other hand that, unlike
colon cancer cells, Cdx2 does not interact with Ku70/80
in leukemia cells, we checked whether Cdx2 has any effect
on the DNA repair activity measured in blood cells using
the in vitro assay. To this end, linear DNA was incubated
with nuclear extracts of Nalm6 cells transfected with the
Cdx2 expressing or with the control pFlag2 plasmids and
the resulting DNA fragments were analyzed by gel elec-
trophoresis. The Figure 4D shows that Cdx2 failed to
inhibit DNA repair activity in leukemia cells, despite its
high level of expression, which clearly contrasted with the
results obtained in colon cancer cells.
Cdx2 inhibits in vivo DNA repair in intestinal cell lines
Next, we analyzed DNA repair in vivo, using the model
developed by Wang et al. (29). This reporter system is
based on the plasmid pEGFP-Pem1-Ad2, consisting in
the GFP-encoding cDNA sequence interrupted by an
intron containing itself an adenovirus exon ﬂanked by
two HindIII restriction sites (Figure 5A). When this
plasmid is cut with HindIII and transfected into cells, it
presents cohesive ends mimicking DSBs, which are then
processed by the NHEJ machinery to circularize the
plasmid and subsequently allow the expression of the
reporter GFP after splicing of the intron.
To evaluate DNA repair activity in vivo, intestinal cells
were cotransfected with the HindIII-linearized plasmid
Figure 3. Ku proteins do not affect signiﬁcantly Cdx2 transcriptional activity. (A) Stimulation of endogenous Cdx2 target genes. HCT116 were
transfected with 1mg of each plasmid in a combined manner as indicated and RNA were extracted and analyzed by RT-qPCR using CDH17, SI or
TBP TaqMan probes. Results are represented as fold induction relative to pFlag (normalized with TBP expression). Data correspond to the mean of
several experiments and error bars represent SEM (n=2). (B) Stimulation of Cdx2 reporter plasmids. HCT116 were transfected with CDH17-luc or
SI-luc reporter plasmids and with indicated expression plasmids. Protein extracts were analyzed for dual luciferase activity. Relative promoter activity
(normalized with Renilla values) of reporter plasmid cotransfected with empty plasmids was set at 1. Data correspond to the mean of several
experiments and error bars represent SEM (n=3). Right panel: FOXO4 transcription factor was used as positive control for Ku70 inhibition on the
6DBE-luc reporter plasmid as described in Brenkman et al. (27).
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ﬂuorescent protein Cherry to normalize the results. The
number of GFP and Cherry positive cells were quantiﬁed
by FACS 72h after transfection and an example of the
green-versus-red ﬂuorescent plot is illustrated on
Figure 5B. When HCT116 cells were cotransfected with
the Cdx2-encoding plasmid, the number of GFP-positive
cells was signiﬁcantly reduced when compared with cells
cotransfected with the control vector pFlag2, indicating
that the presence of Cdx2 alters the activity of DSB
repair in vivo (Figure 5C, left panel). This result was con-
ﬁrmed in HT29 cells (Figure 5C, right panel). Moreover,
miniCdx2, shown above to interact with Ku70/80 like
Cdx2, had the same inhibitory effect as Cdx2, whereas
the truncated form Cdx2[1–220] that lacks the ability to
interact with Ku70/80 proteins, failed to inhibit DNA
repair activity in vivo (Figure 5C, left panel).
Neither Ku proteins and DNA-PKcs recruitment nor
DNA-PKcs autophosphorylation are affected by Cdx2, but
Cdx2 inhibits DNA-PK activity
DNA repair by the C-NHEJ machinery involves sequen-
tial steps of recruitment and activation of several proteins.
The ﬁrst one consists in the recruitment of Ku70/80
heterodimers on the DNA breaks. Because Cdx2 interacts
with Ku70/80 and inhibits DNA repair, we wondered
whether this interaction perturbed Ku70/80 recruitment
on the broken DNA ends. To address this issue, we used
an ELISA method to quantify the amount of Ku70
protein bound on immobilized linear double-strand
DNA molecules mimicking broken DNA ends. Nuclear
extracts were prepared from HCT116 cells transfected
with the Cdx2 encoding or pFlag2 control plasmid and
incubated with the immobilized DNA molecules. As
illustrated in Figure 6A, the presence of Cdx2 did not
change the ability of Ku70 to bind DNA ends, suggesting
that Cdx2 does not alter the recruitment of Ku proteins
onto broken DNA.
Once Ku70/80 proteins have recognized the broken
DNA ends, DNA-PK is recruited into the repair
complex and activated by autophosphorylation (31,32).
Therefore, we followed the recruitment of DNA-PKcs
by coimmunoprecipitation with Ku70 antibody in the
presence or absence of Cdx2. As illustrated on Figure
6B, the presence of Cdx2 in HCT116 cells transfected
with the Cdx2-encoding plasmid did not change the level
Figure 4. Cdx2 inhibits in vitro DNA repair in intestinal cells but not in leukemia cells. (A) NHEJ-C predominates in HCT116 cells. Linear DNA
was incubated with nuclear extracts of HCT116 cells transfected with the siRNA against Ku70 or control siRNA. Processed plasmids were separated
from the linear DNA by gel electrophoresis. When indicated, wortmanin or anti-PARP-1 antibodies were added to the reaction. (B) Cdx2 inhibits
in vitro DNA repair in HCT116 cells. HCT116 cells were transfected with empty vector or pFlag-Cdx2 plasmids and nuclear extracts were assayed
for in vitro DNA repair. When indicated (-ATP), ATP was omitted in the reaction. (C) Cdx2[1–220] mutant does not inhibits DNA repair. HCT116
cells were transfected with empty vector or Cdx2 mutant plasmids as indicated and nuclear extracts were assayed for in vitro DNA repair. When
indicated (-ATP), ATP was omitted in the reaction. Above, expression of Cdx2 and its mutants was checked by western blot on 10mgo f
whole-protein extracts using anti-Flag antibody. Actin was used as loading control. (D) Cdx2 does not alter in vitro DNA repair in Nalm6 cells.
Nalm6 cells were transfected with empty vector or pFlag-Cdx2 plasmids and nuclear extracts were assayed for in vitro DNA repair. Gray arrows
indicate linear plasmid and black arrows multimeric forms of the plasmid.
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antibody, as compared to cells transfected with the
control plasmid pFlag2. As expected, adding ethidium
bromide (EtBr) in the protein extracts disrupted Ku70/
DNA-PKcs interaction; EtBr also compromised Ku70/
Cdx2 interaction, suggesting that it is DNA dependant
(Figure 6B).
We then explored the capacity of the DNA-PKcs to
autophosphorylate. We compared the Thr2609 phosphor-
ylation of DNA-PKcs after etoposide (VP16) treatment
of HCT116 cells transfected with the Cdx2 encoding or
control pFlag2 plasmids. As expected, DSBs induced by
etoposide rapidly enhanced Thr2609 phosphorylation of
DNA-PK which persisted over 24h; the presence of Cdx2
did neither signiﬁcantly modify the level nor the
time-course of phosphorylation (Figure 6C).
DNA-PK phosphorylates several intracellular proteins,
including proteins of the NHEJ pathway as Artemis,
Ku70 and Ku80, H2AX and numerous nuclear DNA-
binding proteins such as tumor suppressor protein p53
(33). We investigated the phosphorylating activity of
DNA-PKcs in an assay based on in vitro solid phase
sandwich ELISA that captures total endogenous p53
protein and detects the level of p53 phosphorylated
on Ser15. Inducible HT29-TW6 and HT29-TG8 cell lines
producing either Cdx2 or GFP as control upon induction
with doxycyclin (15) were either uninduced or treated with
doxycyclin and then treated for one hour with etoposide or
neocarzinostatin to induce DSB or with the vehicle as
control. Nuclear extracts were prepared and tested for
their DNA-PK phosphorylation activity. As presented on
Figure 6D, the level of phosphorylation of the DNA-PKcs
target was signiﬁcantly reduced when Cdx2 expression was
induced by doxycyclin, suggesting that Cdx2 inhibits the
DNA-PK phosphorylation activity.
Cdx2 inhibits cells survival after etoposide treatment in
colon cancer cells but not in leukemia cells
Alteration of DBS repair compromises cell survival
following a genotoxic stress, since the accumulation of
Figure 5. Cdx2 inhibits DNA repair in vivo in intestinal cells. (A) Schematic representation of the pEGFP-Pem1-Ad2 plasmid. G and FP corres-
ponds to the 50 and 30 part of the GFP encoding cDNA. Ad corresponds to the adenoviral intron ﬂanked by two HindIII sites. pCMV indicates the
CMV promoter. (B) Example of green-versus-red ﬂuorescent plots. The experiment was performed in HCT116 transfected with pFlag (left panel) or
pFlag-Cdx2 (right panel). X axis: green ﬂuorescence; Y axis: red ﬂuorescence. (C) Cdx2 alters the in vivo DNA repair. Results represent the mean of
at least four experiments performed in HCT116 (left panel) or HT29 (right panel) transfected with either pFlag, pFlag-Cdx2, pFlag-miniCdx2 or
Cdx2[1-220] plasmids as indicated. The percentage of GFP and Cherry double positive cells in the Cherry positive cell population was set at 1 for
pFlag and error bars represent SEM. Asterisk indicate a signiﬁcant difference (**P<0.01; *P<0.05). Above, expression of Cdx2 and its mutants
was checked by western blot on 10mg of whole protein extracts using anti-Flag antibody. Actin was used as loading control.
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inhibits DNA repair in colon cancer cells but not in
leukemia cells, we tested the consequence of its expression
on cell survival after a genotoxic stress in both types of
cells. For this purpose, we used on the one hand the
human colon cancer cell lines HT29-TW6 and -TW10 in
which Cdx2 expression can be switched on by Doxycyclin
(15), and on the other hand, HCT116 cells transiently
transfected with the Cdx2-encoding plasmid. Cells were
treated for 24h with the topoisomerase II inhibitor
etoposide so as to induce DSBs and allowed to recover
for 2 weeks. Cdx2 expression was followed by western blot
and was conﬁrmed even at 14-days post-transfection
(Figure 7E, left panel). Cell survival was quantiﬁed by
measuring the number of remaining colonies. As
illustrated in Figure 7A, the induction of Cdx2 expression
by Doxycyclin strongly reduced cell survival in the
HT29-TW6 and -TW10 lines as compared to cells
treated with the vehicle, whereas the survival of the
control line HT29-TG8 expressing GFP instead of Cdx2
was unchanged upon Doxycyclin treatment. Similarly, the
transient expression of Cdx2 reduced the survival of
etoposide-treated HCT116 cells (Figure 7B). The effect
was less pronounced in HCT116 than in HT29 cells
likely because the efﬁcacy of Cdx2 expression was lower
by transient cell transfection than in stable cell lines homo-
geneously treated with Doxycyclin. MiniCdx2, which
interacts with Ku70/80 too but lacks the transactivating
domain, also compromised HCT116 cell survival after
etoposide treatment, thus indicating that this effect is
not dependent on the transcriptional activity of Cdx2.
Moreover, the truncated mutant Cdx2[1–220] that does
not interact with Ku proteins, failed to reduce cell
survival, in contrast to Cdx2 and miniCdx2.
Next, these experiments were repeated in leukemia cells
instead of colon cancer cells and cell apoptosis was
followed by FACS after AnnexinV labeling. Results
present the percentage of living cells. In both K562 and
Nalm6 cell lines, etoposide induced a strong decline of
living cells during the ﬁrst week, whether transfected
with the pFlag2 control vector or with the Cdx2-
encoding plasmid (Figure 7C and D). Protein expression
Figure 6. Cdx2 does alter neither Ku proteins and DNA-PKcs recruitment nor DNA-PK autophosphorylation but inhibits DNA-PKcs activity.
(A) Cdx2 does not interfere with DSB Ku70 binding. HCT116 cells were transfected with pFlag (light gray) or Cdx2 (dark gray) expressing plasmid
and Ku70 binding activity was assessed. Results represent the mean of at least four independent experiments. pFlag values were set at 1. (B) Cdx2
does not alter DNA-PKcs recruitment. HCT116 were transfected with either pFlag or pFlag-Cdx2 as indicated and immunoprecipitation was
performed using anti-Ku70 antibodies in the presence or absence of Ethidium Bromide (EtBr) as indicated at the bottom of the ﬁgure.
DNA-PKcs, Ku70 or Cdx2 were revealed by western blot. Twenty micrograms of whole-protein extract were loaded on the right line (input).
(C) Cdx2 does not modify DNA-PKcs autophosphorylation. Time course analysis of the phosphorylation of the DNA-PKcs after etoposide treat-
ment 100mM for 1hour of HCT116 cells transfected with pFlag or pFlag-Cdx2. Phospho-DNA-PKcs was revealed by western blot. b-actin was used
to normalized the amount of loaded proteins. (D) Cdx2 inhibits DNA-PKcs activity. DNA-PKcs activity was assessed in HT29-TW6 or -TG8
(control) cells treated or not with etoposide (VP16) 100mM or neocarzinostatin 200ng/mL for 1hour. Cdx2 expression was induced with doxycyclin
when indicated (dark gray bars). Experiments without doxycyclin and etoposide treatment were considered as references and results were set at 1.
Results illustrate the mean of at least six experiments and error bars represent SEM. Asterisk indicates a signiﬁcant difference (**P<0.01; *P<0.05).
Above, Cdx2 expression was checked by western blot using anti-Cdx2 antibody on 10mg of whole-protein extracts. Actin was used as loading
control.
Nucleic Acids Research,2012, Vol.40, No. 8 3465in K562 was conﬁrmed by western blot at 14 days after
transfection (Figure 7E, right panel). Interestingly, from
1 week after treatment onwards, cells transfected with
Cdx2 entered again a growing phase, in contrast to the
cells transfected with the control plasmid. These results
indicate that, unlike colon cancer cells, Cdx2 does not
compromise cell survival after genotoxic stress in
leukemia cells, and that it even facilitates cell recovery
and/or growth at long term. Hence the effect of Cdx2 on
the response to a genotoxic stress is different in colon
cancer cells compared to leukemia cells.
DISCUSSION
The homeoprotein Cdx2 is recognized as a classical tran-
scription factor that acts via DNA binding to a consensus
AT-rich sequence and activation of transcription by the
transactivation domain (7,35,36). In the present study, we
uncovered a new role for Cdx2 in regulating DNA repair
and we provide evidence that this function does not
require its transactivation domain. This new role
depends on the interaction of Cdx2 with the Ku70/80
proteins and subsequently the inhibition of the NHEJ
DNA repair machinery, independently of the transcrip-
tional activity of Cdx2. Moreover, this new function is
cell type speciﬁc since it is active in intestinal cells where
the gene is normally expressed, but inactive in leukemia
cells where Cdx2 becomes ectopically turned on only
during the transformation process of hematopoietic cells.
This differential function in intestinal and leukemia cells is
correlated to the cell speciﬁc ability of Cdx2 to interact
with Ku70/80. The reason why Cdx2 is unable to interact
with Ku70/80 in leukemia cells remains to be elucidated.
One possibility is that Cdx2 and/or Ku70/80 undergo dif-
ferent post-translational modiﬁcations that differentially
Figure 7. Cdx2 inhibits cell survival in intestinal cells but rather enhances cell recovery in leukemia cells. (A) Cdx2 inhibits cell survival in HT29
cells. HT29-TW6, -TW10 or -TG8 were treated with etoposide in the presence (dark gray) or not (light gray) of doxycyclin and cultured for 2 weeks.
(B) Cdx2 inhibits cell survival in HCT116 cells. HCT116 cells were transfected with either pFlag, pFlag-Cdx2, pFlag-miniCdx2 or pFlag-Cdx2[1-220]
plasmids as indicated, treated with etoposide and cultured for 2 weeks. For A and B, the numbers of clones are represented as the mean of four
independent experiments. Values corresponding to -dox for HT29 or pFlag for HCT116 were set at 1 and error bars represent SEM. Asterisks
indicate a signiﬁcant difference (**P<0.01; *P<0.05). (C) and (D) Cdx2 does not alter cell survival in leukemia cells. Nalm6 or K562 cells were
transfected with vehicle or pFlag-Cdx2 and cell death number was quantiﬁed using annexinV-FITC/propidium iodide at different times after
etoposide treatment as indicated. Results are represented as percentage of living cells. For C and D, results of a representative experiment performed
in triplicates are shown. (E) Control of Cdx2 protein expression. At 3, 8, or 14 days after transfection with indicated plasmids, HCT116 or K562 cells
were lysed in laemmli buffer and Cdx2 expression was tested by western blot on 10mg of whole protein extracts using anti-Flag antibody. Actin was
used as loading control.
3466 Nucleic Acids Research, 2012,Vol.40, No. 8control their interaction in intestinal compared to
leukemia cells. Another possibility is that the interaction
between Cdx2 and Ku70/80 is indirect and depends on an
intermediary factor present in intestinal but not in
leukemia cells.
The binding of Ku70/80 to broken DNA ends is the ﬁrst
step that initiates DNA repair by the conventional
C-NHEJ machinery. In the presence of Cdx2, neither
the binding of Ku70/80 to the DNA nor the recruitment
of DNA-PKcs is altered despite the interaction of Cdx2
with the Ku70/80-DNA-PKcs complex; however, the
kinase activity of the DNA-PK, a major component of
C-NHEJ recruited by Ku70/80, is reduced. This ultimately
results in a decreased DNA repair demonstrated here
using in vivo and in vitro assays. Because Cdx2 does not
compromise DNA recognition by Ku70/80, the Ku70/80
occupancy of the broken DNA ends prevents the recruit-
ment of PARP-1 and thus the activation of the alternative
A-NHEJ pathway normally activated in case of the low
activity of C-NHEJ. Therefore, in the presence of Cdx2,
the reduced activity of C-NHEJ is not compensated by
A-NHEJ.
An increasing number of studies documents new func-
tions for homeoproteins besides their primary role of tran-
scription factors. Especially, several classical or distantly-
related homeodomain-containing proteins interact with
Ku proteins, such as HoxC4, HoxD4, Oct-1, Oct-2 or
Dlx2, and are phosphorylated by the DNA-PK. Yet, the
functional signiﬁcance of this interaction remains elusive
(25,37). The case of the homeoprotein HoxB7, which is
also a partner of Ku70/80 (24), is of particular interest
regarding the results we have obtained for Cdx2. Indeed,
HoxB7 elicits a transformed phenotype in mammary
cancer cells, increases the cell resistance to a genotoxic
stress, and interacts with the Ku70/80-dependent NHEJ
machinery to stimulate DNA repair activity (24); this
signiﬁes that the stimulation of DNA repair by NHEJ is
linked to tumor progression, likely because of the genetic
alterations caused by this error-prone DNA repair
pathway. Inversely, the interaction of Cdx2 with
Ku70/80 in intestinal cells inhibits the NHEJ DNA
repair activity and hampers cell recovery after a genotoxic
stress, associated to a tumor suppressor function of Cdx2
in the gut. Despite their opposite effect on NHEJ activity,
HoxB7 and Cdx2 both interact with Ku70/80 through the
third a-helix of the homeodomain. Further studies will
allow determining the mechanisms by which the homeo-
domains of HoxB7 and Cdx2 act, respectively, to stimu-
late or inhibit the NHEJ activity.This study supports the
hypothesis that the opposite effects reported for Cdx2 in
colon cancers and leukemia, respectively, as tumor sup-
pressor and oncogene, relies at least in part on the fact
that this homeoprotein interacts with a different set of
partners depending on the cellular context. Indeed, in
leukemia cells the ectopically expressed Cdx2 protein is
not able to interact with Ku proteins and to inhibit the
activity of the error-prone pro-oncogenic NHEJ pathway,
whereas in colon cancer cells the interaction of Cdx2 with
the NHEJ machinery reduces the DNA repair activity. In
the normal gut, Cdx2 is expressed in most of the epithelial
cells including the stem cells and transit amplifying cells.
On the basis of the results shown here, we propose that in
this rapidly renewing system, there is a beneﬁt to prevent
DNA repair by NHEJ because of the risk of ﬁxing onco-
genic mutations, whereas when cells keep the DNA breaks
unrepaired, they are eliminated by gatekeeper pathways.
Indeed, several lines of evidence suggest that aberrant
repair of DSBs by error-prone NHEJ could contribute
to the accumulation of genomic alterations, as in the
case of Bloom syndrome for example, and lead to chromo-
somal instability and cancer (38). This is corroborated by
our ﬁnding that a decreased expression of Cdx2 in
Cdx2
+/  heterozygote mice lessens apoptosis in the colon
epithelium after g-irradiation (14), thus rendering the gut
epithelium more resistant to a genotoxic stress. This is also
consistent with the fact that Cdx2 overexpression, together
with Cdx1, in human colon cancer cells leads to
reduced malignancy associated with higher sensitivity to
apoptosis (39). Therefore, the effect of Cdx2 on the NHEJ
DNA repair activity may contribute to the tumor suppres-
sor function attributed to this gene in the gut.
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